<div id="readability-page-1"><p>Bronte Capital Management Pty Ltd. boosted its holdings in  Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,864 shares of the biopharmaceutical company's stock after purchasing an additional 3,890 shares during the quarter. Alnylam Pharmaceuticals comprises approximately  1.7% of Bronte Capital Management Pty Ltd.'s investment portfolio, making the stock its 11th largest holding. Bronte Capital Management Pty Ltd.'s holdings in Alnylam Pharmaceuticals were worth $15,454,000 at the end of the most recent quarter.</p><ul><li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li></ul><p>Other hedge funds have also bought and sold shares of the company. Mediolanum International Funds Ltd acquired a new stake in  Alnylam Pharmaceuticals in the 3rd quarter valued at $11,389,000.  Rakuten Investment Management Inc. acquired a new stake in  Alnylam Pharmaceuticals in the 3rd quarter valued at $14,205,000.  Cerity Partners LLC grew its position in  Alnylam Pharmaceuticals by 171.2% in the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company's stock valued at $12,507,000 after purchasing an additional 17,316 shares during the period.  Campbell &amp; CO Investment Adviser LLC acquired a new stake in  Alnylam Pharmaceuticals in the 3rd quarter valued at $5,790,000.  Finally, Perpetual Ltd acquired a new stake in  Alnylam Pharmaceuticals in the 4th quarter valued at $2,004,000. Institutional investors and hedge funds own  92.97% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts have issued reports on ALNY shares. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a report on Monday. Chardan Capital  reaffirmed a &#34;buy&#34; rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an &#34;overweight&#34; rating and a $527.00 price objective on the stock. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday. Finally, Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, February 17th. One analyst  has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $471.96.</p><ul><li>3 biotech powerhouses poised to thrive amid sector rebound</li></ul><p><b>Check Out Our Latest Stock Analysis on Alnylam Pharmaceuticals</b></p><h2>Insider Activity at Alnylam Pharmaceuticals</h2><p>In other news, EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the sale, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. The trade was a 4.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 38,656 shares of company stock worth $12,370,696. 0.86% of the stock is owned by company insiders. </p><h2>Alnylam Pharmaceuticals Price Performance</h2><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>ALNY opened at $301.11 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $40.20 billion, a price-to-earnings ratio of 82.27 and a beta of 0.31. The firm's fifty day moving average price is $319.41 and its two-hundred day moving average price is $374.99. Alnylam Pharmaceuticals, Inc. has a 1 year low of $245.96 and a 1 year high of $495.55. </p><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts' consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business's revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.44) EPS.  As a group, analysts anticipate that  Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year. </p><h2>Alnylam Pharmaceuticals Profile</h2> (Free Report)<p>Alnylam Pharmaceuticals, Inc <span>NASDAQ: ALNY<span></span></span> is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.  </p><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Alnylam Pharmaceuticals</li></ul><p><strong>Want to see what other hedge funds are holding ALNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALNY

LABU

<p>Bronte Capital Management Pty Ltd. increased its stake in Alnylam Pharmaceuticals, Inc. by 11.1% in Q4, now holding 38,864 shares valued at $15.45 million. Other hedge funds also invested in Alnylam, which is now 92.97% owned by institutional investors. Analysts have given the stock a consensus rating of "Moderate Buy" with an average price target of $471.96. Recent insider sales were reported, with executives selling shares to cover tax obligations. Alnylam's stock performance shows a market cap of $40.20 billion and a P/E ratio of 82.27.</p>

Market Beat

Alnylam Pharma

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Perpetual Limited

Barclays

Argenx

Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY